TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.

Essack Mitha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.